| | | | | | | | | | |
|
|
| Dockets Entered
On July 12, 2005
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1975N-0256
|
| Food Labeling & Label Declaration of Ingredient Requireme
|
|
|
| 1990S-0308
|
| Generic Drug Speeches & Policy and Procedure Guides
|
|
|
| 1997N-0484T
|
| Human Cells, Tissues, and Cellular and Tissue-Based Products; Donor Screening and Testing, and Related Labeling
|
|
|
| 1999P-1340
|
| Declared Eternity eau de Parfum Misbranded
|
|
|
| 2000N-1396
|
| Bioengineered Foods Consumed By Humans or Animals
|
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
|
|
| 2001P-0230
|
| Domestic Marketing & Importation of Transgenic Fish
|
|
|
| 2001P-0345
|
| Listing the color additive yellow #5 for use in food/Drug
|
|
|
| 2002D-0325
|
| Polyvinychloride using Plasticier di-(2-ethyhexyl)phthalate
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
| 2003D-0549
|
| Draft Guidance for Industry: Clozapine Tablets: In Vivo Bioequivalence and In Vitro Dissolution Testing, Revision
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
| 2003V-0131
|
| Laser Light Show
|
|
|
| 2004N-0432
|
| Radioactive Drugs for Certain Research Uses; Public Meeting
|
|
|
| 2004N-0539
|
| Establishing a Docket for the Development of Plasma Standards Public Workshop; Availability
|
|
|
| 2005D-0106
|
| Guidance for Industry on Systemic Lupus Erythematosus Developing Drugs for Treatment
|
|
|
| 2005D-0122
|
| Guidance for Industry on Exploratory IND Studies
|
|
|
| 2005D-0169
|
| Guidance on Useful Written Consumer Medication Information (CMI)
|
|
|
| 2005D-0219
|
| Guidance for Industry: General Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals
|
|
|
| 2005N-0231
|
| Draft Report of the Threshold Working Group, Center for Food Safety and Applied Nutrition, Approaches to Establish Thresholds for Major Food Allergens and for Gluten in Food; Availability
|
|
|
| 2005P-0116
|
| To take the following actions with regard to aqueous-based drugs for inhalation that has been compounded by pharmacy operations
|
|
|
| 2005P-0139
|
| withdrawal of approvals of certain herdwide/flockwide uses of critically and highly important antibiotics pursuant to guidance #152
|
|
|
| 2005V-0053
|
| Projector for a Laser Light Show
|
|
|
| 2005V-0126
|
| Projector for a Laser Light Show
|
|
|
| 2005V-0141
|
| Laser Light Show
|
|
|
| 2005V-0163
|
| Projector for a Laser light Show
|
|
|
| 2005V-0171
|
| Laser Light Show
|
|
|
| 2005V-0194
|
| Laser Light Show
|
|
|
| 1975N-0256
|
| Food Labeling & Label Declaration of Ingredient Requireme
|
|
|
| ANS 14
|
| Office of Legislative Services
|
| Vol #:
|
| 2
|
|
|
| 1990S-0308
|
| Generic Drug Speeches & Policy and Procedure Guides
|
|
|
| RPT
756
|
| Statistical Report - Month of June 2005
|
| Vol #:
|
| 54
|
|
|
| 1997N-0484T
|
| Human Cells, Tissues, and Cellular and Tissue-Based Products; Donor Screening and Testing, and Related Labeling
|
|
|
| EMC 3
|
| S. Levy, RN
|
| Vol #:
|
| 1
|
|
| | | | | | | | |
|
|
| 1999P-1340
|
| Declared Eternity eau de Parfum Misbranded
|
|
|
| EMC 606
|
| J. Butler
|
| Vol #:
|
| 24
|
|
|
| 2000N-1396
|
| Bioengineered Foods Consumed By Humans or Animals
|
|
|
| EMC 11589
|
| No signature
|
| Vol #:
|
| 349
|
|
|
| EMC 11590
|
| R. Holbert
|
| Vol #:
|
| 349
|
|
|
| EMC 11591
|
| A. Olejnik
|
| Vol #:
|
| 349
|
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
|
|
| EMC 14477
|
| C. Stubbs
|
| Vol #:
|
| 342
|
|
|
| EMC 14478
|
| R. Raymond
|
| Vol #:
|
| 342
|
|
|
| EMC 14479
|
| S. Tariot
|
| Vol #:
|
| 342
|
|
|
| EMC 14480
|
| L. Gaviria
|
| Vol #:
|
| 342
|
|
|
| EMC 14481
|
| B. Merlie
|
| Vol #:
|
| 342
|
|
|
| EMC 14482
|
| J. Porras
|
| Vol #:
|
| 342
|
|
|
| EMC 14483
|
| S. Dunn
|
| Vol #:
|
| 342
|
|
|
| 2001P-0230
|
| Domestic Marketing & Importation of Transgenic Fish
|
|
|
| EMC 3173
|
| G. Lehman
|
| Vol #:
|
| 261
|
|
|
| 2001P-0345
|
| Listing the color additive yellow #5 for use in food/Drug
|
|
|
| EMC 1271
|
| A. Erhard
|
| Vol #:
|
| 6
|
|
|
| EMC 1272
|
| W. Chiu
|
| Vol #:
|
| 6
|
|
|
| EMC 1273
|
| S. Dadswell
|
| Vol #:
|
| 6
|
|
|
| EMC 1274
|
| B. Longstreet
|
| Vol #:
|
| 6
|
|
|
| 2002D-0325
|
| Polyvinychloride using Plasticier di-(2-ethyhexyl)phthalate
|
|
|
| EMC 226
|
| E. Woodstock
|
| Vol #:
|
| 4
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
| EMC
480
Attachment
|
| Calorie Control Council
|
| Vol #:
|
| 8
|
|
|
| EMC 481
|
| Mission Possible International
|
| Vol #:
|
| 8
|
|
|
| EMC 482
|
| Mission Possible International
|
| Vol #:
|
| 8
|
|
|
| EMC 483
|
| Mission Possible International
|
| Vol #:
|
| 8
|
|
|
| EMC
484
|
| Calorie Control Council
|
| Vol #:
|
| 8
|
|
|
| EMC 485
|
| Mission Possible International
|
| Vol #:
|
| 8
|
|
|
| EMC 486
|
| Mission Possible International
|
| Vol #:
|
| 8
|
|
|
| EMC 487
|
| Mission Possible International
|
| Vol #:
|
| 8
|
|
|
| 2003D-0549
|
| Draft Guidance for Industry: Clozapine Tablets: In Vivo Bioequivalence and In Vitro Dissolution Testing, Revision
|
|
| | | | | | | | |
|
|
| EMC 1
|
| B. Sachau
|
| Vol #:
|
| 1
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
| EMC 821
|
| S. Arena
|
| Vol #:
|
| 11
|
|
|
| EMC 822
|
| D. Pang
|
| Vol #:
|
| 11
|
|
|
| EMC 823
|
| T. Miller
|
| Vol #:
|
| 11
|
|
|
| EMC 824
|
| J. Clark
|
| Vol #:
|
| 11
|
|
|
| EMC 825
|
| S. Phillips
|
| Vol #:
|
| 11
|
|
|
| 2003V-0131
|
| Laser Light Show
|
|
|
| VRA
3
|
| HFZ-200 to Laser Design Productions Inc
|
| Vol #:
|
| 1
|
|
|
| 2004N-0432
|
| Radioactive Drugs for Certain Research Uses; Public Meeting
|
|
|
| EMC
13
|
| RDRC 0038 - Lawrence Berkeley National Laboratory
|
| Vol #:
|
| 2
|
|
|
| 2004N-0539
|
| Establishing a Docket for the Development of Plasma Standards Public Workshop; Availability
|
|
|
| EMC
2
|
| Plasma Protein Therapeutics Assn (PPTA)
|
| Vol #:
|
| 1
|
|
|
| 2005D-0106
|
| Guidance for Industry on Systemic Lupus Erythematosus Developing Drugs for Treatment
|
|
| EMC
2
Attachment
|
| Aspreva Pharmaceuticals Corp.
|
| Vol #:
|
| 1
|
|
|
| EMC 3
|
| G. Ewing
|
| Vol #:
|
| 1
|
|
|
| 2005D-0122
|
| Guidance for Industry on Exploratory IND Studies
|
|
|
| EMC
2
|
| RDRC #0038
|
| Vol #:
|
| 1
|
|
|
| 2005D-0169
|
| Guidance on Useful Written Consumer Medication Information (CMI)
|
|
|
| EMC
1
|
| Tatia Oden French Memorial Foundation
|
| Vol #:
|
| 1
|
|
|
| EMC 2
|
| B. Sachau
|
| Vol #:
|
| 1
|
|
|
| EMC 3
|
| B. Sachau
|
| Vol #:
|
| 1
|
|
|
| 2005D-0219
|
| Guidance for Industry: General Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals
|
|
|
| EMC 1
|
| B. Sachau
|
| Vol #:
|
| 1
|
|
|
| 2005N-0231
|
| Draft Report of the Threshold Working Group, Center for Food Safety and Applied Nutrition, Approaches to Establish Thresholds for Major Food Allergens and for Gluten in Food; Availability
|
|
|
|
|
|
| EMC 1
|
| S. Rampton
|
| Vol #:
|
| 1
|
|
|
| 2005P-0116
|
| To take the following actions with regard to aqueous-based drugs for inhalation that has been compounded by pharmacy operations
|
|
|
| EMC 1
|
| M. Machacek
|
| Vol #:
|
| 1
|
|
|
| EMC 2
|
| J. Ley
|
| Vol #:
|
| 1
|
|
|
| 2005P-0139
|
| withdrawal of approvals of certain herdwide/flockwide uses of critically and highly important antibiotics pursuant to guidance #152
|
|